Niraparib: beside a new treatment under test
48 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian CancerNot yet recruitingNCT07550205Phase 2/3Report a problem
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid TumorsRecruitingNCT06953323Phase 1/2Report a problem
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT06915025Phase 3Report a problem
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingNCT06682780Phase 1/2Report a problem
- Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian CancerNot yet recruitingNCT05749211Not applicableReport a problem
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results postedReport a problem
- Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid TumorsTerminatedNCT04972110Phase 1/2Results postedReport a problem
- Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingNCT04584255Phase 2Results postedReport a problem
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerCompletedNCT04493060Phase 2Results postedReport a problem
- Niraparib + Dostarlimab + RT in Pancreatic CancerCompletedNCT04409002Phase 2Results postedReport a problem
- Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedNCT04313504Phase 2Results postedReport a problem
- Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2Results postedReport a problem
- European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerCompletedNCT03783949Phase 2Results postedReport a problem
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results postedReport a problem
- A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian CancerCompletedNCT03574779Phase 2Results postedReport a problem
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03431350Phase 2Results postedReport a problem
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results postedReport a problem
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2Report a problem
- ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsWithdrawnNCT06161493Phase 1Report a problem
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsActive, not recruitingNCT06077877Phase 1/2Report a problem
- A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPiStatus unknownNCT05385068Phase 2Report a problem
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingNCT05335993Phase 2Report a problem
- Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2Report a problem
- A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerCompletedNCT05261269Phase 1Report a problem
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedNCT05198804Phase 1/2Report a problem
- Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05162872Phase 2Report a problem
- The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerStatus unknownNCT05162196Phase 2Report a problem
- Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2Report a problem
- A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsCompletedNCT04991480Phase 1Report a problem
- An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1(Programmed Cell Death Protein 1) Antibody in Recurrent/ Advanced Stage Endometrial Cancer PatientsStatus unknownNCT04885413Phase 2Report a problem
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedNCT04826198Phase 1/2Report a problem
- Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1Report a problem
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2Report a problem
- Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentStatus unknownNCT04679064Phase 3Report a problem
- Study of M4344 in Combination With NiraparibWithdrawnNCT04655183Phase 1/2Report a problem
- Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04592237Phase 2Report a problem
- Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast CancerCompletedNCT04508803Phase 2Report a problem
- Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2Report a problem
- ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerTerminatedNCT04267939Phase 1Report a problem
- Phase I Study of SYD985 With Niraparib in Patients With Solid TumorsCompletedNCT04235101Phase 1Report a problem
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Phase 1Report a problem
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)CompletedNCT04170153Phase 1Report a problem
- Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnNCT04149145Phase 1Report a problem
- Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingNCT04068753Phase 2Report a problem
- CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsTerminatedNCT03944902Phase 1Report a problem
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1Report a problem
- PEN-866 in Patients With Advanced Solid MalignanciesStatus unknownNCT03221400Phase 1/2Report a problem
- Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingNCT03016338Phase 2Report a problem